Targeted Dosing as a Precision Health Approach to Pharmacotherapy in Children with Inflammatory Bowel Disease
Datos Bibliográficos
| ID | 15744343 |
|---|---|
| Autores | Anava Wren (Stanford Health Care, autor de correspondencia), K T Park (0000-0002-2133-3598, Stanford Medicine) |
| Año | 2018 |
| Volumen | 20 |
| Número | 9 |
| Páginas | E841-848 |
| Fecha de publicación | 2018-09-01 |
| Peer Reviewed | Sí |
| Open Access | Sí |
| Tipo | ARTICLE |
| Revista | The AMA Journal of Ethic (JOURNAL) |
| Identificadores de la revista | ISSN: 2376-6980 • E-ISSN: 2376-6980 |
| Editorial | American Medical Association (PUBLISHER • US) |
| DOI | 10.1001/amajethics.2018.841 |
| PMID | 30242815 |
| OpenAlex | W2891772682 |
| Idioma | EN |
As clinicians have begun to provide targeted pharmacotherapy for children with inflammatory bowel disease (IBD), several ethical challenges have arisen. In this paper, we review 3 challenges related to applying a precision health approach to pediatric IBD populations: selection of a disease monitoring method, pharmacotherapy optimization, and economic considerations in clinical decision making
Disease · Dosing · Drug · Intensive care medicine · Pharmacotherapy · Therapeutic drug monitoring · Adolescent and Pediatric Healthcare · Inflammatory Bowel Disease · Medicine · Pharmaceutical studies and practices · Internal Medicine · Pharmacology
| Velocidad de citación | historical |
|---|---|
| Altamente citado | No |